This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Vaccine In Vivo Efficacy and Potency Assays
BioVenic offers in vivo efficacy and potency assays for veterinary vaccine development, supporting the evaluation of vaccine protective effects, immune responses to specific pathogens, and overall vaccine performance across companion, poultry, and livestock species. Our platform covers a full suite of challenge-based evaluations—animal challenge studies with morbidity/mortality monitoring, histopathology and pathogen isolation, PD50 and LD50 determinations, and serological assessments including plaque reduction neutralization (PRNT) and hemagglutination inhibition (HI) assays—across models such as dogs, cats, chickens, ducks, pigs, cows, and sheep. We support tailored study designs with expert animal-model and vaccination-route selection, standardized data generation meeting compliance requirements, and detailed reports to advance candidate vaccines through development.
Our Services
Challenge Studies
The fundamental approach to evaluating the efficacy of veterinary vaccines is the challenge study. BioVenic offers a full suite of services to conduct animal challenge studies and complete follow-up observations and evaluations.
- High-quality susceptible animals and various experimental types tailored to your vaccine's needs.
- Expert personnel administer your laboratory products to a set number of animals.
- After a specified period, both immunized and control animals are challenged with virulent strains.
| Observation and Evaluation |
|
| Histopathology Examination |
|
- PD50 Test
The PD50, or the vaccine dose safeguarding 50% of vaccinated animals from the virulent strain, serves as a crucial metric for evaluating veterinary vaccine efficacy. BioVenic offers a full range of services to determine PD50. Our expert team dilutes your vaccine samples into multiple doses (typically a full, a quarter, and a 16th dose) and administers them to target animals. After allowing time for immunity development, both vaccinated and control groups face a dose of virulent virus. Subsequently, statistical methods are employed to calculate the immunizing dose (PD50) that can protect 50% of the animals.
- LD50 Test
LD50, representing the amount of pathogenic agents needed to cause a 50% mortality rate in infected animals, is a key parameter in assessing vaccine tolerance. BioVenic provides LD50 determination services. Animals are divided into control and immunized groups, each subdivided equally. The immunized group receives the veterinary vaccine, and both groups are challenged with pathogenic agents at various dilutions. Post-challenge, BioVenic records morbidity, mortality, lesion, or infection rates in both groups, calculating LD50 values. This data aids in comparing the tolerance of veterinary vaccine samples to virulent challenges at different dosages.
Serological Assessment
- Plaque Reduction Neutralization Test (PRNT)
BioVenic offers the plaque reduction neutralization test (PRNT) as a reliable method for evaluating the efficacy of veterinary vaccines. PRNT results provide valuable information on the ability of a vaccine to neutralize viruses, which can help in veterinary vaccine development.
| A viral suspension at a specified concentration is mixed with serum from animals vaccinated with different dilutions of the vaccine. |
| The mixtures are separately inoculated into host cells for cultivation. |
| The virus infects the cells, leading to replication and the formation of viral plaques. |
| After a designated period, the concentration of virus-neutralizing antibodies is estimated by counting the plaque-forming units. |
| The titer of neutralizing antibodies is determined, representing the amount of antibody required to neutralize the virus and reduce its ability to infect cells. |
- Hemagglutination Assay and Hemagglutination Inhibition Assays
For certain specific viruses, such as influenza viruses, the viral surface contains hemagglutinins that can induce agglutination of red blood cells in certain animals, a phenomenon known as hemagglutination. BioVenic offers hemagglutination assays and hemagglutination inhibition assay services.
| Hemagglutination Assay |
|
| Hemagglutination Inhibition Assay |
|
| Result Interpretation |
|
| Titer Determination |
|
Fig.1 Schematic diagram of quantitative detection of IgM1,2.
Veterinary Vaccine In Vitro Efficacy and Potency Assays
The testing necessary to ensure the efficacy and safety of veterinary vaccines can involve large numbers of animals as well as more significant pain and suffering. BioVenic offers veterinary vaccine in vitro efficacy and potency assays as an alternative method of testing the efficacy of candidate veterinary vaccines.
Related Research
In a study evaluating the in vivo efficacy and potency of novel gene-deleted pseudorabies virus (PRV) live attenuated vaccine candidates derived from a classical/variant strain, researchers constructed two recombinant strains—rPRV FJ-ΔgE/gI and rPRV FJ-ΔTK/gE/gI—using gene editing technology to establish robust protection against circulating variant PRV challenge. In mouse potency models, both recombinant candidates elicited strong humoral and cellular immune responses, characterized by elevated gB-specific antibodies, neutralizing antibody titers, and systemic cytokine production (IFN-γ and IL-4), providing 100% survival protection against lethal wild-type PRV challenge. Subsequent target animal efficacy evaluations in piglets demonstrated that vaccination induced high-level serum neutralizing antibodies and robust cell-mediated immunity without causing clinical adverse effects. Upon challenge with a virulent PRV strain, vaccinated piglets achieved 100% protection, showing complete suppression of fever and typical neurological clinical signs, alongside significantly reduced viral shedding in nasal swabs and reduced histopathological organ damage compared to non-vaccinated controls. Furthermore, the gE/gI gene deletions preserved the DIVA (Differentiating Infected from Vaccinated Animals) capability, highlighting the utility of standardized mouse and swine challenge models for validating the immunogenicity, protective potency, and diagnostic compatibility of next-generation veterinary vaccines.
Fig. 2 The protection of PRV-JM-ΔEK and PRV-JM-ΔEI92K in Mice.3
Why Choose Us?
- We are here to guide you to appropriate vaccination routes and suggest suitable animal models such as dogs, cats, chickens, ducks, pigs, cows, and sheep, tailored to specific veterinary vaccine types.
- Our testing services are designed for precision and consistency, ensuring the reliability of test results.
- Delivering standardized veterinary vaccine efficacy and potency assay outcomes that meet compliance requirements.
Case Study
Researchers conducted a controlled in vivo potency trial in susceptible target animals, assigning groups to receive adjuvant-only control, 1/16 dose, 1/4 dose, or the full intended dose, followed by serological monitoring and a standardized virulent challenge. As shown in the figure, protection rose steeply with vaccine dose: the control group remained at 0%, the 1/16-dose group showed 21% protection, the 1/4-dose group reached 64%, and the full-dose group achieved 96% protection. The PD50 point fell between the 1/16 and 1/4 dose levels, at approximately one-eighth of the intended dose—indicating that the full dose carries a wide potency margin above the regulatory minimum.
Fig. 2 Dose-Response Relationship
Frequently Asked Questions
Q: What types of models are available for in vivo efficacy and potency testing?
A: Depending on your vaccine type—whether viral, bacterial, or antiparasitic—we select or establish appropriate disease challenge models that effectively mimic natural infection routes and clinical pathology. Because specific animal strain requirements, housing conditions, and facility biosafety levels varies, we recommend contacting our technical support team to discuss and confirm the most suitable host model for your project.
Q: What are the general requirements for submitting vaccine test samples?
A: Clients must provide detailed information regarding vaccine composition, storage conditions, concentration, and formulation type (such as adjuvanted or liquid). Samples should be shipped frozen or under temperature-controlled conditions on dry ice or ice packs, accompanied by a completed Sample Submission Form. To protect sample integrity, avoid repeated freeze-thaw cycles prior to dispatch. Because specific stability requirements, minimum volumetric quantities, and biohazard transport regulations vary by pathogen and assay type, please consult our technical specialists before shipping your samples to ensure compliant and seamless delivery.
Q: How do you establish and evaluate protective potency during animal challenge studies?
A: Potency evaluation is customized based on standard regulatory frameworks and specific target pathogens. Following vaccination protocols, animals are challenged with characterized strain isolates, after which we monitor parameters such as survival rates, body temperature, clinical scores, histopathology, and pathogen shedding. In tandem, humoral and cellular immune responses are quantified via assays like ELISA or serum neutralization. Because challenge doses and endpoints depend heavily on vaccine mechanisms, we encourage clients to consult our technical team to finalize an optimal protocol tailored to your target efficacy metrics.
Q: What is the typical turnaround time for an in vivo efficacy and potency study?
A: Turnaround times depend largely on the experimental design, including the vaccination schedule, required booster shots, observation periods, and post-challenge follow-up duration. Typically, studies range from several weeks to a few months from animal acclimation to final report generation. Additional downstream analytical testing, such as comprehensive pathology or serology panels, may also influence the timeline. To ensure your project meets critical submission deadlines, we recommend contacting our technical support team early to review project timelines, resource scheduling, and study design details.
BioVenic's in vivo efficacy and potency assay services for veterinary vaccines are customized to align with your project's unique needs and specific characteristics. When you choose us, you gain access to trustworthy data and expert guidance, propelling your veterinary vaccine development forward. Contact us today and take the next step towards your vaccine's success!
References
- Broecker, Felix, et al. "Chemotherapy-induced, broadly reactive autoantibodies in a colon cancer patient." Cureus 14.11 (2022).
- Image retrieved from Figure 1 "Principle of the assay for IgM quantification", Broecker, Felix, et al., 2022, used under CC BY 4.0. https://doi.org/10.7759/cureus.31954. The original image was modified by changing the title to "Schematic diagram of quantitative detection of IgM"
- Wang, Shanghui, et al. "Construction of two recombinant pseudorabies viruses with deletion of virulence genes and evaluation of their immune protection in mice and piglets." Vaccines 13.4 (2025): 359. https://doi.org/10.3390/vaccines13040359. Used under CC BY 4.0. Without Modification.
